纳武利尤单抗联合瑞拉利单抗治疗晚期黑色素瘤:RELATIVITY-047 4年更新
RELATIVITY-047 2/3期随机研究的4年描述性更新显示,在既往未治疗的晚期黑色素瘤患者中,纳武利尤单抗联合瑞拉利单抗对比纳武利尤单抗单药,4年无进展生存率分别为30.6%与23.6%,总生存率分别为52.0%与42.8%,客观缓解率分别为43.9%与33.4%,未发现新的或非预期安全信号。
要点
- 4年无进展生存率联合组30.6% vs 单药组23.6%,PFS获益维持。
- 4年总生存率联合组52.0% vs 单药组42.8%,联合组数值上更优。
- 4年黑色素瘤特异性生存率联合组59.7% vs 单药组49.6%。
核心结论
- 经过4年随访,纳武利尤单抗联合瑞拉利单抗对比纳武利尤单抗单药,在既往未治疗的晚期黑色素瘤患者中显示出持久的结局改善。
- 与其他免疫肿瘤联合方案相比,观察到的持久获益伴随着更低的毒性代价。
研究设计与样本
- RELATIVITY-047为2/3期随机研究,本次报告4年描述性更新分析。
- 患者接受纳武利尤单抗480 mg联合瑞拉利单抗160 mg固定剂量组合,对比纳武利尤单抗480 mg静脉注射每4周一次。
- 主要终点为盲法独立中心审查(BICR)评估的无进展生存期(PFS),其他终点包括黑色素瘤特异性生存期(MSS)。
主要发现
- 最短随访45.3个月时,联合组对比单药组4年PFS率分别为30.6%(95%CI 25.4-35.9)与23.6%(95%CI 18.9-28.5),PFS改善维持。
- 联合组对比单药组4年OS率分别为52.0%(95%CI 46.6-57.1)与42.8%(95%CI 37.5-47.9),联合组数值上更优。
- 联合组对比单药组ORR分别为43.9%(95%CI 38.7-49.3)与33.4%(95%CI 28.6-38.6),ORR差异维持。
- 联合组对比单药组4年MSS率分别为59.7%(95%CI 54.1-64.8)与49.6%(95%CI 44.0-54.9)。
- 大多数预设亚组的疗效倾向于联合组,未发现新的或非预期安全信号。
关键数值与推荐
- 4年PFS率:纳武利尤单抗联合瑞拉利单抗组30.6%(95%CI 25.4-35.9) vs 纳武利尤单抗单药组23.6%(95%CI 18.9-28.5)。
- 4年OS率:联合组52.0%(95%CI 46.6-57.1) vs 单药组42.8%(95%CI 37.5-47.9)。
- ORR:联合组43.9%(95%CI 38.7-49.3) vs 单药组33.4%(95%CI 28.6-38.6)。
- 4年MSS率:联合组59.7%(95%CI 54.1-64.8) vs 单药组49.6%(95%CI 44.0-54.9)。
临床怎么用
- 对于既往未治疗的晚期黑色素瘤患者,纳武利尤单抗480 mg联合瑞拉利单抗160 mg固定剂量组合每4周静脉给药一次是研究中的干预方案。
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In phase 2/3 randomized RELATIVITY-047, nivolumab plus relatlimab demonstrated a statistically significant improvement in progression-free survival (PFS), a clinically meaningful but not statistically significant improvement in overall survival (OS), and a numerically higher objective response rate (ORR) versus nivolumab alone in patients with previously untreated advanced melanoma. METHODS: Descriptive 4-year updated analyses in patients treated with nivolumab 480 mg plus relatlimab 160 mg fixed-dose combination versus nivolumab 480 mg intravenously every 4 weeks are presented. Primary endpoint was PFS by blinded independent central review (BICR). Other endpoints included melanoma-specific survival (MSS). RESULTS: At 45.3 months' minimum follow-up, nivolumab plus relatlimab versus nivolumab PFS improvement was maintained: 4-year PFS rates were 30.6 % (95 % CI, 25.4-35.9) versus 23.6 % (95 % CI, 18.9-28.5); OS was numerically better with 4-year OS rates of 52.0 % (95 % CI, 46.6-57.1) versus 42.8 % (95 % CI, 37.5-47.9); and ORR difference was maintained at 43.9 % (95 % CI, 38.7-49.3) versus 33.4 % (95 % CI, 28.6-38.6), respectively. 4-year MSS rates were 59.7 % (95 % CI, 54.1-64.8) for nivolumab plus relatlimab and 49.6 % (95 % CI, 44.0-54.9) for nivolumab. Efficacy across the majority of prespecified subgroups favored the combination. No new or unexpected safety signals were identified. CONCLUSIONS: With 4 years of follow-up, nivolumab plus relatlimab demonstrated durable improvement in outcomes versus nivolumab monotherapy for patients with previously untreated advanced melanoma. The durable benefit observed comes at a lower toxicity cost compared with other immuno-oncology combinations. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03470922.
引用
- Lipson EJ, Stephen Hodi F, Tawbi H, et al. Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update. Eur J Cancer. 2025. PMID: 40513285. doi:10.1016/j.ejca.2025.115547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。